Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Salubris Biotherapeutics Announces $35 Million in Financing

2024-04-22
GAITHERSBURG, MD, Salubris Biotherapeutics, a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, announced a new capital infusion of $35 million.
Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, announced a new capital infusion of $35 million to fund continued research and development of clinical and pre-clinical programs. SalubrisBio also provided progress updates for JK07, the first investigational antibody fusion protein for heart failure, JK08, the first investigational IL15-CTLA4 antibody fusion for solid tumors and JK06, a first-in-class biparatopic antibody-drug conjugate (ADC) targeting a known tumor antigen.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors